CD24 and neoplasm: To address the heterogeneity of tumor phenotype between patients and the heterogeneous EVs that are emitted from each cell, we apply the specificity of TENPO to separately isolate either HER2+ or CD24+ EV sub-populations and perform a combined analysis of the biomarkers packaged within these complementary sets of EVs.